Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Mu-opiate Receptor Engagement on Microbial Translocation and Residual Immune Activation in HIV-infected, ART Suppressed Opioid Use Disorder Patients Initiating Medication-assisted Treatment

X
Trial Profile

Effects of Mu-opiate Receptor Engagement on Microbial Translocation and Residual Immune Activation in HIV-infected, ART Suppressed Opioid Use Disorder Patients Initiating Medication-assisted Treatment

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine/naloxone (Primary) ; Methadone (Primary) ; Naltrexone (Primary) ; Antiretrovirals
  • Indications Opioid-related disorders
  • Focus Pharmacodynamics
  • Acronyms AMOHI-1
  • Most Recent Events

    • 11 Jul 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
    • 11 Jul 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.
    • 06 Jul 2023 Planned End Date changed from 31 Jul 2027 to 30 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top